Literature DB >> 31335391

National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.

Alice P Chen1, Mariam Eljanne2, Lyndsay Harris3, Shakuntala Malik4, Nita L Seibel4.   

Abstract

With advances in genetic testing and its common usage, the field of precision medicine has exploded in the field of oncology. The National Cancer Institute is uniquely positioned to lead in this area of research through its wide network of investigators, partnerships with pharmaceutical companies in drug development, and laboratory capabilities. It has developed a portfolio of trials as part of a Precision Medicine Initiative that uses various basket/umbrella designs to increase the understanding of treatment of cancer through genetic selection and targeted therapies. This article describes these trials, ALCHEMIST, LungMAP, NCI/NRG ALK Trial, MPACT, NCI-MATCH, and pediatric MATCH, and their contributions to the area of precision medicine.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31335391      PMCID： PMC6658131          DOI： 10.1097/PPO.0000000000000389

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  11 in total

1.  Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.

Authors:  Chih-Jian Lih; Robin D Harrington; David J Sims; Kneshay N Harper; Courtney H Bouk; Vivekananda Datta; Jonathan Yau; Rajesh R Singh; Mark J Routbort; Rajyalakshmi Luthra; Keyur P Patel; Geeta S Mantha; Savitri Krishnamurthy; Karyn Ronski; Zenta Walther; Karin E Finberg; Sandra Canosa; Hayley Robinson; Amelia Raymond; Long P Le; Lisa M McShane; Eric C Polley; Barbara A Conley; James H Doroshow; A John Iafrate; Jeffrey L Sklar; Stanley R Hamilton; P Mickey Williams
Journal:  J Mol Diagn       Date:  2017-02-07       Impact factor: 5.568

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Authors:  Carl E Allen; Theodore W Laetsch; Rajen Mody; Meredith S Irwin; Megan S Lim; Peter C Adamson; Nita L Seibel; D Williams Parsons; Y Jae Cho; Katherine Janeway
Journal:  J Natl Cancer Inst       Date:  2017-05-01       Impact factor: 13.506

4.  FDA drug approval summary: erlotinib (Tarceva) tablets.

Authors:  Martin H Cohen; John R Johnson; Yeh-Fong Chen; Rajeshwari Sridhara; Richard Pazdur
Journal:  Oncologist       Date:  2005-08

5.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

6.  U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Authors:  Shakun M Malik; Virginia Ellen Maher; Karen E Bijwaard; Robert L Becker; Lijun Zhang; Shenghui W Tang; Pengfei Song; Qi Liu; Anshu Marathe; Brenda Gehrke; Whitney Helms; Diane Hanner; Robert Justice; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

7.  Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial.

Authors:  Chih-Jian Lih; David J Sims; Robin D Harrington; Eric C Polley; Yingdong Zhao; Michele G Mehaffey; Thomas D Forbes; Biswajit Das; William D Walsh; Vivekananda Datta; Kneshay N Harper; Courtney H Bouk; Lawrence V Rubinstein; Richard M Simon; Barbara A Conley; Alice P Chen; Shivaani Kummar; James H Doroshow; Paul M Williams
Journal:  J Mol Diagn       Date:  2015-11-18       Impact factor: 5.568

Review 8.  ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Authors:  Ramaswamy Govindan; Sumithra J Mandrekar; David E Gerber; Geoffrey R Oxnard; Suzanne E Dahlberg; Jamie Chaft; Shakun Malik; Margaret Mooney; Jeffrey S Abrams; Pasi A Jänne; David R Gandara; Suresh S Ramalingam; Everett E Vokes
Journal:  Clin Cancer Res       Date:  2015-12-15       Impact factor: 12.531

9.  Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

Authors:  Shakun M Malik; Richard Pazdur; Jeffrey S Abrams; Mark A Socinski; William T Sause; David H Harpole; John J Welch; Edward L Korn; Claudio Dansky Ullmann; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
View more
  11 in total

Review 1.  New Frontiers for Fairer Breast Cancer Care in a Globalized World.

Authors:  Didier Verhoeven; Claudia Allemani; Cary Kaufman; Sabine Siesling; Manuela Joore; Etienne Brain; Mauricio Magalhães Costa
Journal:  Eur J Breast Health       Date:  2021-03-31

2.  Tumor Heterogeneity Research and Innovation in Biologically Based Radiation Therapy From the National Cancer Institute Radiation Research Program Portfolio.

Authors:  Jeffrey C Buchsbaum; Michael G Espey; Ceferino Obcemea; Jacek Capala; Mansoor Ahmed; Pataje G Prasanna; Bhadrasain Vikram; Julie A Hong; Beverly Teicher; Molykutty J Aryankalayil; Michelle A Bylicky; C Norman Coleman
Journal:  J Clin Oncol       Date:  2022-03-04       Impact factor: 50.717

Review 3.  Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies.

Authors:  Dylan C Brock; Scott Demarest; Tim A Benke
Journal:  Neurotherapeutics       Date:  2021-09-30       Impact factor: 6.088

Review 4.  Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.

Authors:  F J Crowley; R E O'Cearbhaill; D C Collins
Journal:  Cancer Treat Rev       Date:  2021-05-23       Impact factor: 13.608

5.  Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.

Authors:  Alice P Chen; Shivaani Kummar; Nancy Moore; Lawrence V Rubinstein; Yingdong Zhao; P Mickey Williams; Alida Palmisano; David Sims; Geraldine O'Sullivan Coyne; Christina L Rosenberger; Mel Simpson; Kanwal P S Raghav; Funda Meric-Bernstam; Stephen Leong; Saiama Waqar; Jared C Foster; Mariam M Konaté; Biswajit Das; Chris Karlovich; Chih-Jian Lih; Eric Polley; Richard Simon; Ming-Chung Li; Richard Piekarz; James H Doroshow
Journal:  JCO Precis Oncol       Date:  2021-01-12

Review 6.  The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why?

Authors:  Agnieszka Kaczmarska; Patrycja Śliwa; Monika Lejman; Joanna Zawitkowska
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

7.  A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).

Authors:  Angela R Bradbury; Ju-Whei Lee; Jill Bennett Gaieski; Shuli Li; Ilana F Gareen; Keith T Flaherty; Benjamin A Herman; Susan M Domchek; Angela M DeMichele; Kara N Maxwell; Adedayo A Onitilo; Shamsuddin Virani; SuJung Park; Bryan A Faller; Stefan C Grant; Ryan C Ramaekers; Robert J Behrens; Gopakumar S Nambudiri; Ruth C Carlos; Lynne I Wagner
Journal:  Cancer       Date:  2021-12-10       Impact factor: 6.921

8.  Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

Authors:  Mary W Redman; Vassiliki A Papadimitrakopoulou; Katherine Minichiello; Fred R Hirsch; Philip C Mack; Lawrence H Schwartz; Everett Vokes; Suresh Ramalingam; Natasha Leighl; Jeff Bradley; Jieling Miao; James Moon; Louise Highleyman; Crystal Miwa; Michael L LeBlanc; Shakun Malik; Vincent A Miller; Ellen V Sigal; Stacey Adam; David Wholley; Caroline Sigman; Beverly Smolich; Charles D Blanke; Karen Kelly; David R Gandara; Roy S Herbst
Journal:  Lancet Oncol       Date:  2020-10-27       Impact factor: 41.316

9.  Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.

Authors:  Nathan D Seligson; Todd C Knepper; Susanne Ragg; Christine M Walko
Journal:  Clin Pharmacol Ther       Date:  2020-07-16       Impact factor: 6.875

Review 10.  Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.

Authors:  Yuichi Yamamoto; Norihiro Kanayama; Yusuke Nakayama; Nobuko Matsushima
Journal:  J Pers Med       Date:  2022-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.